Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diziquit-MD
- Development stage
- Unknown
- Lead developer
- Vanprom Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Diziquit-MD is a branded generic fixed-dose combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) marketed by Vanprom Lifesciences. It is formulated as a mouth-dissolving (orally disintegrating) tablet primarily indicated for the symptomatic treatment of vertigo of various origins, motion sickness, and inner ear balance disorders such as Meniere's disease. Cinnarizine acts as a calcium channel blocker and antihistamine, improving microcirculation in the inner ear and reducing vestibular over-excitation. Dimenhydrinate, a combination of diphenhydramine and 8-chlorotheophylline, acts as an H1 antihistamine and anticholinergic agent, suppressing vestibular system activity and targeting the brain's vomiting center to control nausea and dizziness.
- Brand names
- Diziquit-MD
- Other names
- Diziquit MDDiziquit-MD Tablet Raspberry
02
Targets
5-HT2 (5-HT2 receptor family)ADOR (Adenosine receptors)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)LTCC (Voltage-gated calcium channel (L-type))mAChR (Muscarinic acetylcholine receptors)CaV3 (Caveolin-3)
Beyond the preview
Go deeper on Diziquit-MD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diziquit-MD.